We are united in our mission to deliver patient-needed therapies sooner.
We are curious, bold, and share a passion for thinking differently.
SMPA is committed to accelerating scientific and therapeutic breakthroughs on behalf of patients in critical disease areas across psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies.
SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc., and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.
Our parent company, Sumitomo Pharma Co., Ltd., was established in 1897 and has an extensive history of supporting health and wellbeing. Sumitomo Pharma is a member of the Sumitomo Group, which has a history of about 400 years. Learn more about Sumitomo Pharma’s history here.
We are industry-leading experts in drug development, business, engineering, science, and technology. Together, we operate with data-driven insights, agility, and scientific rigor to deliver the therapies that people need most.
Board of Directors
Global reach with an expansive U.S. footprint
SMPA is part of a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the U.S., China, Canada, and Europe as well as talent, knowledge, and resources across a wide spectrum of technologies and therapeutic areas.
Spirovant Sciences, an SMPA subsidiary, is focused on changing the course of cystic fibrosis and other pulmonary diseases.